Truist lowered the firm’s price target on AnaptysBio (ANAB) to $20 from $30 and keeps a Hold rating on the shares. The firm is removing ANB032 in atopic dermatitis due to the recent Phase 2b trial failure and lowering its estimates for imsidolimab, noting that its rosnilimab estimates in rheumatoid arthritis remain unchanged.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Broadcom tops $1T market cap on AI enthusiasm: Morning Buzz
- Biotech Alert: Searches spiking for these stocks today
- Adobe outlook disappoints, Kroger announces $7.5B buyback: Morning Buzz
- AnaptysBio price target lowered to $36 from $90 at Guggenheim
- AnaptysBio price target lowered to $40 from $56 at Wells Fargo